Газоносність вугільних пластів та фізико-механічнині властивості порід покрівлі і підошви поля шахти № 1 ”Тяглівська” Львівсько-Волинського басейну

Сопоставлены данные по изучению газоносности угольных пластов поля шахты № 1 ―Тягловская‖ и физико-механическим свойствам пород их непосредственной кровли и подошвы. Благоприятными яляются условия для выработки пластов b4, n8 в, n8. Несколько сложнее – для пластов n9, n7 в, n7 1, что вызвано низкой стойкостью пород кровли. Наиболее сложной прогнозируется ситуация для эксплуатации пласта n7 из-за низной стойкости и способности его кровли к обрушениям. Угольные пласты (кроме b4) находятся в метановой зоне. Их газоносность значительна, содержание метана в газовой смеси высокое. Это будет составлять дополнительные трудности при эксплуатации.Data on studies of the gas-bearing potential of coal seams of the Tyagliv-1 mine field are correlated as well as physical-mechanical properties of their immediate base and roof. Favorable conditions are known to exist for working of the seams b4, n8 в, n8. Somewhat more composite ones are observed for the seams n9, n7в, n7 1 that was caused by low stability of the roof rocks. The most composite situation is forecasted for exploitation of the seam n7 one to low stability and ability of its roof for landslides. Coal seams (exsepting b4) lie in the methane zone. Their gas-bearing potential is suffcient, methane content in a gas mixture is high. That will cause additional difficalties in the process of exploitation

Atopic dermatitis and food sensitization in South African toddlers: Role of fiber and gut microbiota

The pathogenesis of atopic dermatitis (AD) is complex and related to allergic responses and defects in skin barrier function. In common with many atopic diseases, the prevalence of AD has been increasing across the world.1 One of the theories for this increase is increased hygiene and urbanization-related changes in the environment, which can affect the human microbiome.2 Previous studies have found associations between the composition of the early gut microbiome and development of atopic conditions, including AD.3 Although the rate of atopic conditions, including AD and food allergy, is increasing on all continents, the prevalence of these diseases is still lower in African countries.1 This is especially interesting because individuals of African origin who live in Western countries, such as African Americans, are at a higher risk for severe AD.4 This variation places Africa in a special position; studying African populations is necessary not only to find ways to prevent increases of allergy conditions in African countries but also to provide important clues to the causes of this global increasing of allergic conditions. Young children who have developed AD in African communities with a low incidence of atopic disease might be the transitional group. In the current study, we have, for the first time to our knowledge, analyzed the fecal microbiota composition of a group of young black African children aged 12 to 36 months old with and without AD living in the same community in Cape Town, South Africa. Our primary goal was to examine whether toddlers with AD and control toddlers from Cape Town have different microbiomes in terms of bacterial richness and diversity. We also aimed to investigate the differences in the relative abundance for different operational taxonomic units between these 2 groups. In our subgroup analyses, we further tested the effect of multiple environmental factors on the gut microbiome in these children

Neurodevelopment of Preterm infants at 24 Month After Neonatal Supplementation of a Prebiotic Mix: A Randomized Trial

OBJECTIVES: Fetal brain maturation is disrupted by preterm birth. Inflammation during the neonatal period might further harm neurodevelopmental outcomes. This study aimed to determine the effect of short chain galacto-oligosaccharides/long chain fructo-oligosaccharides/pectin-derived acidic oligosaccharides (scGOS/lcFOS/pAOS) on neurodevelopmental outcomes measured by Bayley Scales of Infant and Toddler Development (BSID) in preterm infants at 24 months. METHODS: In this randomized controlled trial, scGOS/lcFOS/pAOS or placebo was supplemented between days 3-30 of life. Serum samples at day 1, 7, 14 were analysed for cytokine levels. Stool samples at day 1, 7, 14 and 30 were measured for bacterial count and bifidobacteria percentage. At 24 months corrected age infants were followed-up by a blinded pediatric psychologist for the BSID II or III. RESULTS: 77/101 (76%) eligible infants participated in the follow-up study. Neurodevelopmental outcomes were not different in the scGOS/lcFOS/pAOS and placebo group. Infections during the neonatal period, lower percentages of bifidobacteria at day 7 (F = 3.8, p = 0.05) and day 14 (F = 5.0, p = 0.02) and higher levels of Interleukine (IL)-1β (F = 4.0, p = 0.04) and IL-8 (F = 8.0, p = 0.01) at day 7 are associated with lower mental developmental index. Lower psychomotor outcomes are associated with IL-2 (F = 4.0, p = 0.05), IL-4 (F = 6.0, p = 0.02) at birth and interferon gamma at day 7 (F = 4.4, p = 0.04). CONCLUSIONS: scGOS/lcFOS/pAOS showed no significant improvement of neurodevelopmental outcomes at 24 months in preterm infants. Infections, lower bifidobacteria counts and higher serum cytokine levels during the neonatal period were associated with lower neurodevelopmental outcomes at 24 months of age indicating the relevance of microbiome and immune responses in neurodevelopmental processes

Neurodevelopment of Preterm Infants at 24 Months After Neonatal Supplementation of a Prebiotic Mix: A Randomized Trial

Fetal brain maturation is disrupted by preterm birth. Inflammation during the neonatal period may further harm neurodevelopmental outcomes. The present study aimed to determine the effect of short-chain galacto-oligosaccharides/long-chain fructo-oligosaccharides/pectin-derived acidic oligosaccharides (scGOS/lcFOS/pAOS) on neurodevelopmental outcomes measured by Bayley Scales of Infant and Toddler Development in preterm infants at 24 months. In this randomized controlled trial, scGOS/lcFOS/pAOS or placebo was supplemented between days 3 and 30 of life. Serum samples at day 1, 7, and 14 were analyzed for cytokine levels. Stool samples at day 1, 7, 14, and 30 were measured for bacterial count and bifidobacteria percentage. At 24 months corrected age infants were followed up by a blinded pediatric psychologist for the Bayley Scales of Infant and Toddler Development II or III. Seventy-seven of one hundred one (76%) eligible infants participated in the follow-up study. Neurodevelopmental outcomes were not different in the scGOS/lcFOS/pAOS and placebo group. Infections during the neonatal period, lower percentages of bifidobacteria at day 7 (F = 3.8, P = 0.05) and day 14 (F = 5.0, P = 0.02) and higher levels of Interleukine (IL)-1β (F = 4.0, P = 0.04) and IL-8 (F = 8.0, P = 0.01) at day 7 are associated with lower mental developmental index. Lower psychomotor outcomes are associated with IL-2 (F = 4.0, P = 0.05), IL-4 (F = 6.0, P = 0.02) at birth, and interferon gamma at day 7 (F = 4.4, P = 0.04). scGOS/lcFOS/pAOS showed no significant improvement of neurodevelopmental outcomes at 24 months in preterm infants. Infections, lower bifidobacteria counts, and higher serum cytokine levels during the neonatal period were associated with lower neurodevelopmental outcomes at 24 months of age indicating the relevance of microbiome and immune responses in neurodevelopmental processe

Lower transplacental antibody transport for measles, mumps, rubella and varicella zoster in very preterm infants

Maternal antibodies, transported over the placenta during pregnancy, contribute to the protection of infants from infectious diseases during the first months of life. In term infants, this protection does not last until the first recommended measles-mumps-rubella vaccination at 14 months in the Netherlands, while these viruses still circulate. The aim of the study was to investigate the antibody concentration against measles, mumps, rubella and varicella (MMRV) in mothers and preterm infants or healthy term infants at birth. Antibody concentrations specific for MMRV were measured in cord blood samples from preterm (gestational age <32 weeks and/or birth weight <1500 g) and term infants, and matched maternal serum samples, using a fluorescent bead-based multiplex immune-assay. Due to lower placental transfer ratios of antibodies against MMRV in 96 preterm infants (range 0.75-0.87) compared to 42 term infants (range 1.39-1.65), the preterm infants showed 1.7-2.5 times lower geometric mean concentrations at birth compared to term infants. Maternal antibody concentration is the most important determinant of infant antibody concentration against MMRV. Preterm infants benefit to a lesser extent from maternal antibodies against measles, mumps, rubella and varicella than term infants, posing them even earlier at risk for infectious diseases caused by these still circulating viruse

Neutral and acidic oligosaccharides supplementation does not increase the vaccine antibody response in preterm infants in a randomized clinical trial

In preterm infants, a decreased immunological response and lower serological effectiveness are observed after immunizations due to ineffectiveness of both humoral and cellular immune mechanisms. To determine the effect of 80% neutral oligosaccharides [small-chain galacto-oligosaccharides/long-chain fructo-oligosaccharides (scGOS/lcFOS)] in combination with 20% pectin-derived acidic oligosaccharides (pAOS) on antibody concentrations after DTaP-IPV-Hib immunization in preterm infants. In this randomized clinical trial, preterm infants with gestational age <32 weeks and/or birth weight <1500 g received enteral supplementation with scGOS/lcFOS/pAOS or placebo (maltodextrin) between days 3 and 30 of life. Blood samples were collected at 5 and 12 months of age. In total, 113 infants were included. Baseline and nutritional characteristics were not different in both groups. Geometric mean titers were not different after prebiotic supplementation at 5 months, Ptx (37/44 EU/ml), FHA (78/96 EU/ml), Prn (78/80 EU/ml), Diphtheria (0.40/0.57 IU/ml), Tetanus (0.74/0.99 IU/ml) and Hib (0.35/0.63 µg/ml), and at 12 months Ptx (55/66 EU/ml), FHA (122/119 EU/ml), Prn (116/106 Eu/ml), Diphtheria (0.88/1.11 IU/ml), Tetanus (1.64/1.79 IU/ml) and Hib (2.91/2.55 µg/ml). Enteral supplementation of neutral (scGOS/lcFOS) and acidic oligosaccharides (pAOS) does not improve the immunization response in preterm infants. Controlled-Trials.com ISRCTN16211826 ISRCTN1621182

Number of samples tested, geometric mean concentration (GMCs) and transplacental transport ratios of antibodies to measles, mumps, rubella and varicella zoster in preterm and term infants.

<p><b>NOTE</b>. Maternal serum samples were obtained from mothers between 2 days before and after delivery and cord serum samples were obtained from umbilical cords. CI, confidence intervals; IU, international unit; RU, RIVM unit; IgG, immunoglobulin G; *p<0.01, ^†p<0.05.</p

Percentage of protected preterm and term infants and their mothers at birth to <i>measles, mumps, rubella, varicella zoster</i>.

<p>IU, international unit; RU, RIVM unit.</p

Individual maternal-to cord blood antibody concentrations of measles (IU/ml), mumps (RU/ml), rubella (IU/ml) and varicella (IU/ml).

<p>Individual maternal-to cord blood antibody concentrations of measles (IU/ml), mumps (RU/ml), rubella (IU/ml) and varicella (IU/ml).</p

Transplacental transport ratio of measles, mumps, rubella and varicella with 95% confidence intervals.

<p>Transplacental transport ratio of measles, mumps, rubella and varicella with 95% confidence intervals.</p